Ledger.Open graph →
SEC Form D · filed January 17, 2024

Comanche Biopharma Corp

Offering
$75.0M
Sold
$37.5M
Exemption
Rule 506(b)
Industry
Pharmaceuticals
Location
CONCORD, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (22)

Brendan S. Bulik-Sullivan · Concord, MADirectorMuzammil S. Mansuri · Concord, MADirectorDavid S. Grayzel · Concord, MADirectorAnn S. Taylor · Concord, MADirectorAllison S. August · Concord, MAExecPaul S. Antinori · Cocoa, FLExecAllyson S. Felix · Concord, MADirectorThomas S. Johnson · Concord, MAExec · DirectorScott S. Gottlieb · Concord, MADirectorKetan S. Patel · Concord, MADirectorMichael S. Young · Chicago, ILExecBrendan S. Bulik-Sullivan · Concord, MADirectorMuzammil S. Mansuri · Concord, MADirectorAnn S. Taylor · Concord, MADirectorAllison S. August · Concord, MAExecPaul S. Antinori · Concord, MAExecAllyson S. Felix · Concord, MADirectorDavid S. Grayzel · Concord, MADirectorThomas S. Johnson · Concord, MAExec · DirectorScott S. Gottlieb · Concord, MADirectorKetan S. Patel · Concord, MADirectorMichael S. Young · Chicago, ILExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗